Sign in
Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Journal article   Peer reviewed

Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Valeria Santini, Rami S. Komrokji, Mikkael A. Sekeres, Michael Robert Savona, Pierre Fenaux, Yazan F. Madanat, Esther Oliva, Rena Buckstein, Anna Jonášová, Ulrich Germing, …
Clinical lymphoma, myeloma and leukemia, Vol.24, pp.S192-S192
2024-09

Metrics

5 Record Views

Details